

List of Progress in Hematology "Review Series" 2018-2019

2019

Molecular pathogenesis of leukemia and stem cells (Edited by Masahiro Kizaki)

1. Tan TK, Zhang C, Sanda T. Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia. Int J Hematol. 2019; 109:5-17.
<https://link.springer.com/article/10.1007/s12185-018-2518-z>
2. Ito K, Bonora M, Ito K. Metabolism as master of hematopoietic stem cell fate. Int J Hematol. 2019; 109:18-27.
<https://link.springer.com/article/10.1007/s12185-018-2534-z>
3. Takei H, Kobayashi SS. Targeting transcription factors in acute myeloid leukemia. Int J Hematol. 2019; 109:28-34.
<https://link.springer.com/article/10.1007/s12185-018-2488-1>
4. Portilho NA, Kobayashi M, Yoshimoto M. What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells. Int J Hematol. 2019; 109:35-40.
<https://link.springer.com/article/10.1007/s12185-018-2537-9>

Recent progress in allogeneic stem cell transplantation using alternative stem cell sources (Edited by Junya Kanda)

1. Kawamura K. Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation. Int J Hematol. 2019; 110:22-29
<https://link.springer.com/article/10.1007/s12185-019-02597-y>
2. Sugita J. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol. 2019; 110:30-8.
<https://link.springer.com/article/10.1007/s12185-019-02660-8>

3. Yamamoto H. Single cord blood transplantation in Japan; expanding the possibilities of CBT. *Int J Hematol.* 2019; 110:39-49.
<https://link.springer.com/article/10.1007/s12185-019-02672-4>
4. Maung KK, Horwitz ME. Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells. *Int J Hematol.* 2019; 110:50-58.
<https://link.springer.com/article/10.1007/s12185-019-02670-6>

Epigenetic abnormalities and therapies for hematological (Edited by Toshio Kitamura)

1. Brunetti L, Gundry MC, Goodell MA. New insights into the biology of acute myeloid leukemia with mutated NPM1. *Int J Hematol.* 2019; 110:150-60.
<https://link.springer.com/article/10.1007/s12185-018-02578-7>
2. Duchmann M, Itzykson R. Clinical update on hypomethylating agents. *Int J Hematol.* 2019; 110:161-9.
<https://link.springer.com/article/10.1007/s12185-019-02651-9>
3. Sashida G, Oshima M, Iwama A. Deregulated Polycomb functions in myeloproliferative neoplasms. *Int J Hematol.* 2019; 110:170-8.
<https://link.springer.com/article/10.1007/s12185-019-02600-6>
4. Asada S, Kitamura T. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms. *Int J Hematol.* 2019; 110:179-86.
<https://link.springer.com/article/10.1007/s12185-018-2563-7>

2018

Iron metabolism and the related diseases (Edited by Hideo Harigae)

1. Tomas Ganz T. Iron and infection. *Int J Hematol.* 2017; 107:7-15.
<https://link.springer.com/article/10.1007/s12185-017-2366-2>
2. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. *Int J Hematol.* 2018; 107:16-30.
<https://link.springer.com/article/10.1007/s12185-017-2373-3>
3. Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. *Int J Hematol.* 2018; 107:31-43.
<https://link.springer.com/article/10.1007/s12185-017-2365-3>
4. Furuyama K, Kaneko K. Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia. *Int J Hematol.* 2018; 107:44-54.
<https://link.springer.com/article/10.1007/s12185-017-2368-0>
5. Gattermann N. Iron overload in myelodysplastic syndromes (MDS). *Int J Hematol.* 2018; 107:55-63.
<https://link.springer.com/article/10.1007/s12185-017-2367-1>

New immunotherapy-based approach in allogeneic hematopoietic stem cell transplantation (Edited by Yoshinobu Maeda)

1. Matsuoka K. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives. *Int J Hematol.* 2018; 107:130-7.

<https://link.springer.com/article/10.1007/s12185-017-2386-y>

2. Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. *Int J Hematol.* 2018; 107:138-50.

<https://link.springer.com/article/10.1007/s12185-017-2364-4>

3. Elssen CHMJ, Ciurea SO. NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect? *Int J Hematol.* 2018; 107:151-6.

<https://link.springer.com/article/10.1007/s12185-017-2379-x>

Advances in immunotherapy for hematological malignancies (Edited by Norimitsu Kadowaki)

1. Mehta RS, Randolph B, Daher M, Rezvani K. NK cell therapy for hematologic malignancies. *Int J Hematol.* 2018; 107: 262-70.

<https://link.springer.com/article/10.1007/s12185-018-2407-5>

2. Kawamoto H, Masuda K, Nagano S, Maeda T. Cloning and expansion of antigen-specific T cells using iPS cell technology: development of “off-the-shelf” T cells for the use in allogeneic transfusion settings. *Int J Hematol.* 2018; 107: 271-7.

<https://link.springer.com/article/10.1007/s12185-018-2399-1>

3. Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. *Int J Hematol.* 2018; 107: 278-85.

<https://link.springer.com/article/10.1007/s12185-018-2405-7>

Current status and progress of lymphoma research in East Asian countries (Edited by Junji Suzumiya)

1. Yoo KH, Lee H, Suh C. Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving

Survival of Lymphoma (CISL) trial. *Int J Hematol.* 2018; 107: 395-404.

<https://link.springer.com/article/10.1007/s12185-018-2403-9>

2. Shi Y. Current status and progress of lymphoma management in China. *Int J Hematol.* 2018; 107: 405-12.

<https://link.springer.com/article/10.1007/s12185-018-2404-8>

3. Chan JY, Lim ST. Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. *Int J Hematol.* 2018; 107: 413-9.

<https://link.springer.com/article/10.1007/s12185-018-2406-6>

4. Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan. *Int J Hematol.* 2018; 107: 420-7.

<https://link.springer.com/article/10.1007/s12185-018-2430-6>

The regulatory signal for normal and abnormal hematopoiesis (Edited by Fumio Arai)

1. Sigurdsson V, Miharada K. Regulation of unfolded protein response in hematopoietic stem cells. *Int J Hematol.* 2018; 107:627-33.

<https://link.springer.com/article/10.1007/s12185-018-2458-7>

2. Wilkinson AC, Yamazaki A. The hematopoietic stem cell diet. *Int J Hematol.* 2018; 107: 634-41.

<https://link.springer.com/article/10.1007/s12185-018-2451-1>

3. Sugimura R. The significance and application of vascular niche in the development and maintenance of hematopoietic stem cells. *Int J Hematol.* 2018; 107: 642-5.

<https://link.springer.com/article/10.1007/s12185-018-2450-2>

4. Hosokawa K, Arai F. The role of telomere binding molecules for normal and abnormal hematopoiesis. *Int J Hematol.* 2018; 107: 646-55.

<https://link.springer.com/article/10.1007/s12185-018-2432-4>

Chronic Myeloid Leukemia (Edited by Yosuke Minami)

1. Rea D, Cayuela J-M. Treatment-free remission in patients with chronic myeloid leukemia. *Int J Hematol.* 2018; 108: 355-64.

<https://link.springer.com/article/10.1007/s12185-017-2295-0>

2. Inoue A, Kobayashi CI, Shinohara H, Miyamoto K, Yamauchi N Yuda J, et al. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. *Int J Hematol.* 2018; 108: 365-70.

<https://link.springer.com/article/10.1007/s12185-018-2519-y>